ArticleBMJ health & care informatics2026
Machine learning framework for early identification of high-spending Crohn's disease patients using administrative claims.
Article in BMJ health & care informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo develop and evaluate a machine learning (ML) model that predicts Crohn's disease (CD) patients responsible for the top quartile of healthcare spending.
methodsDe-identified commercial claims (2016-2018) from ~267 000 continuously enrolled members in a Midwestern state were analysed, including 994 CD cases. Monthly data for each patient was aggregated into data points that included healthcare spending amounts, encounter interactions, demographics and binary flags for diagnoses, procedures and drug codes. Seven algorithm families were tuned using five-fold cross-validation (January 2016 to September 2017) and tested prospectively (November 2017 to February 2018). Monthly performance evaluations assessed the accuracy of predicting high-cost healthcare spending, using 4-month and 1-month historical cost analyses for comparison.
resultsML models predicted an average of 80% of the dollars spent by top-quartile members during the 4-month evaluation period, compared with 67% for the 4-month baseline and 62% for the prior-month benchmark. The models identified an average of 51 new members entering the high-cost group each month, nearly double the yield of the 4-month historical method. These ML models more accurately anticipated inpatient encounters that drove excess spending. DISCUSSION: Claims-based ML offers actionable lead time for payers and clinicians to enhance monitoring, adjust biological therapy or schedule elective care before emergency admissions occur. Because this framework relies exclusively on standard claim fields, it can be quickly extended to other episodic, high-variance conditions.
conclusionProspectively tested, claims-only ML models enhance short-term risk stratification in CD by identifying future high-cost patients. Future studies should confirm the clinical impact, cost savings and ensure equitable performance across diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.